Skip to main content
. 2015 Jan 1;5(1):23–42. doi: 10.7150/thno.10202

Figure 6.

Figure 6

Schematic illustration of co-delivery of therapeutic drugs and therapeutic small RNA using free aptamer or aptamer-conjugated nanoparticles. The choice of drugs and small RNA is based on rational design and subject to extensive in vivo testing. Therapeutic agents can be directly conjugated with aptamers without further encapsulated into a nanoparticle, while aptamers can either be grafted on to the surface of nanoparticles as a targeting agent, and/or conjugated with a drug.